Combat Medical’s EUR 3.13 million Series A first close is a notable outlier in a market that has made early-stage medtech harder to finance. The UK-based company is raising fresh capital to move its hyperthermic intravesical chemotherapy (HIVEC) platform into a pivotal Phase 3 FDA study, a step that typically stretches both budgets and investor patience.
The round was led by the T&J Meyer Family Foundation, with participation from Varia Ventures and NW Angel Fund, among other investors. Combat Medical previously disclosed the first close at £2.6 million in March 2026.
Why this funding matters now
The medical device sector can still attract large pools of capital, but the distribution has become uneven. Sector data shows strong Q1 2025 funding of $2.6 billion across 132 deals, while early-stage funding dropped sharply to $26 million in March 2025. In that context, a specialist Series A raise for a device with meaningful regulatory and clinical execution risk reads as an against-trend signal.
It also underlines a practical reality in medtech: platforms that can point to real-world usage and clinical adoption tend to stay fundable even when the broader market tightens.
The asset: a niche platform in bladder cancer
Combat Medical’s focus is a device-assisted therapy for bladder cancer using HIVEC, which delivers heated chemotherapy into the bladder. The company positions the approach as a bladder-sparing alternative to radical cystectomy for patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC), where treatment pathways can become limited.
The niche matters. Hyperthermic drug delivery sits in a specialised corner of medtech, with high development costs and non-trivial regulatory hurdles. That makes the financing more difficult, but it can also reduce competitive density if the clinical evidence and workflow adoption hold up.
Commercial footprint: installed base as a de-risking datapoint
Investors cited Combat Medical’s leadership in device-assisted therapies and potential to disrupt standards of care, pointing to an installed base of more than 350 systems and over 100,000 HIVEC treatments. Separately reported figures indicate more than 350 systems installed across 40-plus countries and 55,000-plus treatments completed.
While the exact reconciliation between treatment counts is not disclosed in the announcement, the central takeaway is the same: this is not a pre-revenue concept device. A global footprint and repeat clinical usage can support the underwriting case that hospitals will adopt the workflow and that the company can build an evidence package beyond controlled trials.
Use of proceeds: the pivotal gate is the Phase 3 FDA trial
The proceeds are earmarked to fund a Phase 3 FDA trial, known as HIVEC HEAT, targeting BCG-unresponsive NMIBC. For medtech investors, this is the value inflection point that can determine whether the platform remains a regional commercial product or becomes a scalable, regulator-backed standard option.
Key questions for the next 12-24 months are executional rather than conceptual:
- Trial design and endpoints: Whether the study is powered and structured to support a clear regulatory pathway.
- Enrollment velocity: Phase 3 timelines often slip in oncology-adjacent indications; delays can force additional financing rounds under weaker terms.
- Evidence translation to payers and guidelines: FDA progress does not automatically equal reimbursement traction or guideline adoption.
What the investor mix signals
A lead from a family foundation alongside venture and angel participation suggests a syndicate comfortable with longer duration risk, which is often required in device-led oncology pathways. It also implies confidence in management’s ability to run both a global commercial footprint and a pivotal US trial in parallel.
That parallel execution is a common fault line in growth-stage medtech. Maintaining installed-base growth while running a Phase 3 program can strain leadership bandwidth, quality systems, and post-market support if not resourced correctly.
What to watch next
- Phase 3 launch details: sites, enrollment targets, and milestone timing for HIVEC HEAT.
- Regulatory pathway clarity: any FDA feedback that tightens or de-risks the approval route.
- Commercial momentum: updates on installed base growth and utilisation per system.
- Strategic partnerships: progress on drug activation collaborations and expansion into other indications such as peritoneal or colorectal applications.
- Future financing: whether the company signals a second close or additional capital needs tied to trial duration.